title: Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity.
abstract: This study was designed to evaluate in 45 hypertensive patients with left ventricular hypertrophy (LVH) the effects of a 6-month course with one of three different antihypertensive regimens (the calcium channel blocker isradipine, the angiotensin converting enzyme inhibitor spirapril in monotherapy, or a combination of the two drugs, n = 15 per group) on blood pressure, LVH regression, and various functional correlates of LVH. All three treatment modalities decreased significantly LV mass index by an average of 10%, although the combination had the greatest blood pressure-lowering effect and spirapril had the least, as assessed by office resting pressures, ambulatory monitoring, and isometric grip testing. There was no correlation between magnitude of blood pressure lowering and degree of LVH regression. The effects of treatment on pressor hormone profiles differed among groups, as spirapril tended to suppress angiotensin II and norepinephrine, whereas isradipine had opposite effects. Exercise tolerance was prolonged by all three regimens, but significantly more by the combination. All three regimens decreased significantly the double product by 10% to 15%. Indices of electrophysiologic stability calculated from analysis of ambulatory electrocardiogram exhibited significant improvement in several parameters such as QRS duration, presence of late potentials, and measures of heart rate variability, resulting in fewer episodes of simple or complex ventricular arrhythmia. We conclude that all three regimens produce significant LVH regression associated with improved functional capacity and electrical stability. These results reflect the sum of the differential hemodynamic and hormonal effects exerted by each treatment modality.
authors.affiliation: Tzanio Hospital, Piraeus, Greece.
authors.forename: A J
authors.initials: AJ
authors.lastname: Manolis
authors.forename: D
authors.initials: D
authors.lastname: Beldekos
authors.forename: S
authors.initials: S
authors.lastname: Handanis
authors.forename: G
authors.initials: G
authors.lastname: Haralabidis
authors.forename: J
authors.initials: J
authors.lastname: Hatzissavas
authors.forename: S
authors.initials: S
authors.lastname: Foussas
authors.forename: D V
authors.initials: DV
authors.lastname: Cokkinos
authors.forename: M
authors.initials: M
authors.lastname: Bresnahan
authors.forename: I
authors.initials: I
authors.lastname: Gavras
authors.forename: H
authors.initials: H
authors.lastname: Gavras
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D018660:Blood Pressure Monitoring, Ambulatory; D004311:Double-Blind Method; D004656:Enalapril / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology*; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy* / Q000503:physiopathology*; D017275:Isradipine / Q000008:administration & dosage*; D008297:Male
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004656:Enalapril; C052555:spirapril; D017275:Isradipine